PTSD Market Projected to Exceed $25 Billion by 2031
The Post Traumatic Stress Disorder (PTSD) market is forecast to reach $25.64 billion by 2031, growing at a compound annual growth rate of 5.08% from 2026.
The global market for Post Traumatic Stress Disorder (PTSD) treatments is projected to expand to $25.64 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.08% during the 2026-2031 forecast period. The market was valued at $19.04 billion in 2025.
Key drivers for this growth include the increased adoption of selective serotonin reuptake inhibitors (SSRIs), the expanding clinical use of psychedelic-assisted therapies, and the commercialization of digital therapeutics. Despite regulatory setbacks, such as the rejection of MDMA therapy, market momentum is maintained through a focus on combination pharmacology and digital health solutions.
Selective serotonin reuptake inhibitors (SSRIs) held the largest market share at 38.96% in 2025. However, psychedelic-assisted therapies are expected to experience the fastest growth, with an anticipated CAGR of 8.42%. Adults constituted the largest patient segment, accounting for 81.22% of the market in 2025, while the pediatric and adolescent segment is projected to grow at a 7.21% CAGR.
North America led the market in 2025 with a 36.10% revenue share, while the Asia-Pacific region is anticipated to grow the fastest at a 6.88% CAGR through 2031. Pharmacotherapy remains the dominant treatment modality, holding an 85.05% share in 2025, though digital therapeutics are demonstrating significant advancement.
Factors contributing to the market's expansion include rising PTSD prevalence and diagnosis rates globally, acceleration in late-stage clinical trials for novel agents, the application of AI in drug repurposing, and increased access through tele-psychiatry services. These elements collectively support the steady growth trajectory of the PTSD market.